Novan to Participate in the Virtual Investor Roundtable Event
12. November 2021 09:00 ET
|
Novan, Inc.
– Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17th at 1:00 PM ET – DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
10. November 2021 05:55 ET
|
Novan, Inc.
– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – –...
Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19
09. November 2021 08:35 ET
|
Novan, Inc.
– Data indicate that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe under the conditions of preclinical study – – Company believes the...
Novan Announces Fireside Chat Hosted by Jonathan Aschoff, Ph.D. of ROTH Capital Partners
04. November 2021 09:00 ET
|
Novan, Inc.
– Company highlights rationale of strategic pathway towards potential commercialization in collaboration with commercial solutions provider, Syneos Health – – Discusses recent progress and expected...
Novan to Report Third Quarter 2021 Financial Results on November 10, 2021
03. November 2021 09:00 ET
|
Novan, Inc.
DURHAM, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2021 financial results on Wednesday,...
Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum
02. November 2021 08:30 ET
|
Novan, Inc.
– Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received...
Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206
23. September 2021 08:00 ET
|
Novan, Inc.
– SB206 demonstrates continued favorable safety profile consistent with previous studies and meets Company’s expectations – – Pre-NDA meeting with the FDA, as well as conduct of customary stability...
Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
20. September 2021 09:00 ET
|
Novan, Inc.
DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...
Novan Announces Strategic Priorities and Outlines Key Milestones
09. September 2021 07:00 ET
|
Novan, Inc.
– Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum – – Late-stage...
Novan Engages Syneos Health as Commercial Solutions Provider for SB206
08. September 2021 09:00 ET
|
Novan, Inc.
– Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in...